Filing Flows › Ocular Therapeutix (OCUL) › Q2 2026
Ocular Therapeutix (OCUL) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 3, 2026
Ocular Therapeutix (OCUL) reported revenue of $13.5M for the second quarter 2026 (Q2 2026), +0.1% from a year earlier and +25% from the quarter before. Operating margin was -609.3%, net loss $78.8M (584.5% of revenue).
Ocular Therapeutix, Q2 2026: revenue $13.5M (+0.1% year over year), operating margin -609.3%, net loss $78.8M, operating cash flow −$67.3M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $13.5M | +25% | +0.1% |
| Operating profit | −$82.1M | — | — |
| Net earnings | −$78.8M | — | — |
| Operating cash flow | −$67.3M | — | — |
What changed
Revenue was $13.5M in Q2 2026, roughly flat year over year and up 25% from the previous quarter.
Operating costs exceeded revenue by $82.1M, an operating margin of -609.3%. Total costs grew 18% against flat revenue. The fastest-growing cost line was General & admin (+54%). The quarter ended with a net loss of $78.8M, narrower than the previous quarter's $88.6M loss.
Operating cash flow was −$67.3M. Non-cash charges added back $1.9M of depreciation and amortization and $14.6M of share-based compensation. Working capital and other items used $5.0M. Capital expenditures of $3.4M exceeded it, leaving free cash flow of −$70.6M.
Questions
What was Ocular Therapeutix's revenue in the second quarter 2026?
Ocular Therapeutix (OCUL) reported revenue of $13.5M for the second quarter 2026 (Q2 2026), +0.1% from a year earlier and +25% from the quarter before.
Was Ocular Therapeutix profitable in the second quarter 2026?
Operating loss was $82.1M (-609.3% of revenue) and net loss $78.8M.
Source: Ocular Therapeutix 10-Q on SEC EDGAR.